Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
im interested in alibaba...how can I get in it now?
$LJPC - La Jolla Pharmaceutical Company Closes Offering of Common Stock
6:29 PM ET 7/28/14 | BusinessWire
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the closing of its underwritten public offering of 5,395,000 shares of common stock at a public offering price of $10.50 per share, which includes the partial exercise of the underwriters' option to purchase up to an additional 720,000 shares of common stock. Gross offering proceeds are approximately $56.6 million, including proceeds from the partial exercise of the underwriters' option to purchase additional shares, before deducting customary underwriting discounts and commissions and offering expenses.
La Jolla intends to use the net proceeds from the offering for general corporate purposes, including funding its ongoing and future clinical trials, and for general and administrative expenses.
Jefferies LLC acted as sole book-runner for the offering. Chardan Capital Markets, LLC, H.C. Wainwright & Co., LLC, LifeSci Capital, LLC and Noble Financial Group, Inc. acted as co-managers for the offering.
The securities described above were offered pursuant to a shelf registration statement (File No. 333-197092), including a base prospectus, which was declared effective by the United States Securities and Exchange Commission ("SEC") on July 11, 2014. The specific terms of the offering are described in a prospectus supplement filed with the SEC in connection with the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering was made only by means of the prospectus supplement and accompanying prospectus, copies of which may be obtained at the SEC's website at www.sec.gov, or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140728006300r1&sid=cmtx6&distro=nx
SOURCE: La Jolla Pharmaceutical Company
View data
La Jolla Pharmaceutical Company George F. Tidmarsh, M.D., Ph.D. President & Chief Executive Officer (858) 207-4264 gtidmarsh@ljpc.com or Chester S. Zygmont, III Director of Finance (858) 207-4262 czygmont@ljpc.com
$LJPC - La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
9:14 AM ET 7/23/14 | BusinessWire
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the pricing of an underwritten offering of 4,800,000 shares of its common stock, offered at a price of $10.50 per share. La Jolla has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock. The offering is expected to close on or about July 28, 2014, subject to customary closing conditions. Jefferies LLC is acting as sole book-runner for the offering. Chardan Capital Markets, LLC, H.C. Wainwright & Co., LLC, LifeSci Capital, LLC and Noble Financial Group, Inc. are acting as co-managers for the offering.
Gross offering proceeds will be $50,400,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by La Jolla. La Jolla intends to use the net proceeds from the underwritten offering for general corporate purposes, including funding its ongoing and future clinical trials, and for general and administrative expenses.
The securities described above are being offered pursuant to a shelf registration statement (File No. 333-197092), including a base prospectus, which was declared effective by the United States Securities and Exchange Commission ("SEC") on July 11, 2014. The specific terms of the offering are described in a prospectus supplement to be filed with the SEC in connection with the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering will be made only by means of the prospectus supplement and accompanying prospectus, copies of which may be obtained at the SEC's website at www.sec.gov, or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com.
This press release contains statements relating to the proposed offering that are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties, such as the risk that the conditions to the closing of the offering will not be satisfied. All forward-looking statements are based upon information available to La Jolla on the date the statements are first published. La Jolla undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140723005713r1&sid=cmtx6&distro=nx
SOURCE: La Jolla Pharmaceutical Company
View data
La Jolla Pharmaceutical Company George F. Tidmarsh, M.D., Ph.D. President & Chief Executive Officer (858) 207-4264 gtidmarsh@ljpc.com and La Jolla Pharmaceutical Company Chester S. Zygmont, III Director of Finance (858) 207-4262 czygmont@ljpc.com
$LJPC - La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of Common Stock
4:01 PM ET 7/22/14 | BusinessWire
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold by La Jolla.
Jefferies LLC is acting as sole book-runner for the offering. La Jolla intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
La Jolla intends to use the net proceeds from the underwritten offering for general corporate purposes, funding its ongoing and future clinical trials, general and administrative expenses and potential future acquisitions and other strategic purposes.
The securities described above are being offered pursuant to a shelf registration statement (File No. 333-197092), including a base prospectus, which was declared effective by the United States Securities and Exchange Commission ("SEC") on July 11, 2014. The specific terms of the offering are described in a prospectus supplement to be filed with the SEC in connection with the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering will be made only by means of the prospectus supplement and accompanying prospectus, copies of which may be obtained at the SEC's website at www.sec.gov, or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com.
This press release contains statements relating to the proposed offering that are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties, such as the risk that the conditions to the closing of the offering will not be satisfied. All forward-looking statements are based upon information available to La Jolla on the date the statements are first published. La Jolla undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140722006497r1&sid=cmtx6&distro=nx
SOURCE: La Jolla Pharmaceutical Company
View data
La Jolla Pharmaceutical Company George F. Tidmarsh, M.D., Ph.D. President & Chief Executive Officer 858-207-4264 gtidmarsh@ljpc.com and Chester S. Zygmont, III Director of Finance 858-207-4262 czygmont@ljpc.com
$OWW - Orbitz Worldwide Announces Pricing of Secondary Common Stock Offering by Selling Stockholder
10:25 AM ET 7/17/14 | GlobeNewswire
Orbitz Worldwide, Inc. (NYSE:OWW) today announced the pricing of an underwritten public offering of 34 million shares of its common stock by an affiliate of Travelport Limited (the "Selling Stockholder"). The underwriter has a 30-day option to purchase up to an additional 5 million shares from the Selling Stockholder. Orbitz Worldwide will not receive any proceeds from the offering. The offering is scheduled to close on July 22, 2014, subject to customary closing conditions.
Credit Suisse Securities (USA) LLC is serving as the sole book-running manager. Credit Suisse Securities (USA) LLC may offer the shares of common stock from time to time for sale in one or more transactions on the New York Stock Exchange, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. The offering of securities is made only by means of a written prospectus and related prospectus supplement, which together will form a part of Orbitz Worldwide's effective registration statement. The prospectus and prospectus supplement relating to the offering will be filed with the U.S. Securities and Exchange Commission ("SEC") and will be available on the SEC's website at www.sec.gov. Alternatively, when available, copies of the prospectus and prospectus supplement relating to this offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York 10010, or by calling 800-221-1037 or by emailing a request to newyork.prospectus@credit-suisse.com.
The shares are being offered pursuant to an effective registration statement filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About Orbitz Worldwide
Orbitz Worldwide (NYSE:OWW) is a leading global online travel company using technology to transform the way consumers around the world plan and purchase travel. Orbitz Worldwide operates the consumer travel planning sites Orbitz (orbitz.com), ebookers (ebookers.com), HotelClub (hotelclub.com) and CheapTickets (cheaptickets.com). Also within the Orbitz Worldwide family, Orbitz Partner Network (orbitz.com/OPN) delivers private label travel technology solutions to a broad range of partners including some of the world`s largest airlines and travel agencies, and Orbitz for Business (orbitzforbusiness.com) delivers managed travel solutions for companies of all sizes. Orbitz Worldwide makes investor relations information available at investors.orbitz.com.
CONTACT: Media Contact:
+1-312-894-6890
press@orbitz.com
Investor Contact:
Brian Wolf
+1-312-260-8301
OWWIR@orbitz.com
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwODk4MzcjMjk0MDE=
$URZ - Uranerz Announces Upsizing of Offering to US$12 Million
Jul 18, 2014 09:00:00 (ET)
Uranerz Announces Upsizing of Offering to US$12 Million
CASPER, WYOMING--(Marketwired - Jul 18, 2014) - Uranerz Energy Corporation ("Uranerz" or the "Company") (TSX:URZ)(NYSE MKT:URZ)(FRANKFURT:U9E) is pleased to announce that due to demand, it has increased the size of its previously announced offering of units on July 16, 2014 (the "Offering") to raise gross proceeds of US$12 million consisting of 9,600,000 units of the Company at a price per unit of US$1.25 ("Units"). Each Unit will be comprised of one share of the Company's common stock ("Common Share"), and one half of one common share purchase warrant, with each whole warrant ("Warrant") exercisable to purchase one additional Common Share for a period of 30 months following the closing of the Offering at an exercise price of US$1.60, subject to adjustment and acceleration provisions. The Warrants will be transferable, however, the Company will not apply for listing of the Warrants on any securities exchange.
The Offering is led by Haywood Securities Inc. and Cantor Fitzgerald Canada Corporation (the "Lead Agents") on behalf of a syndicate of agents including H.C. Wainwright & Co., LLC, and Laurentian Bank Securities Inc. (the "Agents"). All offers of Units in the United States will be made by U.S. registered broker-dealers. H.C. Wainwright & Co., LLC will only be offering the Units in the United States.
The Company has been informed by the Lead Agents that the books are now closed. Closing of the Offering is anticipated to take place on July 25, 2014, subject to satisfaction of the conditions to closing set forth in an Agency Agreement, including receipt of approval of the NYSE MKT LLC and the Toronto Stock Exchange.
The Company anticipates that the net proceeds from the offering will be utilized to continue development and operations of mining facilities, including wellfields, at the Company's Nichols Ranch ISR Uranium Project. Additionally, proceeds will be used for working capital and other general corporate purposes.
The Units are being offered through the Agents pursuant to a prospectus supplement to the Company's effective shelf registration statement on Form S-3 (File No. 333-196686) previously filed with the Securities and Exchange Commission and pursuant to a prospectus supplement to the Company's shelf prospectus filed with certain Canadian regulators in each of the provinces of Canada, except Quebec, pursuant to the multi-jurisdictional disclosure system. Copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained from the Securities and Exchange Commission website at http://www.sec.gov, from the System for Electronic Document Analysis and Retrieval (SEDAR) website at http://www.sedar.com or from the Lead Agents at:
Haywood Securities Inc.
Suite 700 - 200 Burrard Street
Vancouver, BC
V6C 3L6
Attention: Michelle Jankovich
Telephone: 604-697-7126
E-mail: mjankovich@haywood.com
Cantor Fitzgerald Canada Corporation
Suite 1500 - 181 University Avenue
Toronto, ON
M5H 3M7
Attention: Maylin Cui
Telephone: 416-350-8155
E-mail: ecmcanada@cantor.com
This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or jurisdiction.
About Uranerz
Uranerz Energy Corporation is a U.S.-domiciled uranium company. The Company's Nichols Ranch unit is its first ISR uranium mine. Uranerz controls a large strategic land position in the central Powder River Basin. The Company's management team has specialized expertise in the ISR uranium mining method and a record of licensing, constructing and operating ISR uranium projects. The Company has entered into long-term uranium sales contracts for a portion of its planned production with Exelon and one other of the largest nuclear utilities in the country.
Further Information
For further information, please contact Derek Iwanaka, Manager of Investor Relations at 1-800-689-1659 or by email at investor@uranerz.com. Alternatively, please review the Company's filings with the Securities and Exchange Commission at www.sec.gov, or visit the Company's profile on SEDAR at www.sedar.com.
Forward-looking Statements
This press release may contain or refer to "forward-looking information" and "forward-looking statements" within the meaning of applicable United States and Canadian securities laws, which may include, but are not limited to, statements with respect to the Offering size and terms and gross proceeds from the Offering, completion of the Offering, anticipated use of proceeds, and all statements which describe future activities or express intentions, plans or expectations and all statements in the future tense. All such forward-looking statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, including, the risks and uncertainties outlined in our most recent financial statements and reports and registration statement filed with the Securities and Exchange Commission (available at www.sec.gov) and with Canadian securities administrators (available at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. We do not undertake to update forward-looking statements, except as required by law.
Uranerz Energy Corporation
Derek Iwanaka
Manager of Investor Relations
1-800-689-1659
investor@uranerz.com
(MORE TO FOLLOW) Dow Jones Newswires
July 18, 2014 09:00 ET (13:00 GMT)
GE Seeks to Raise $3.1 Billion in Synchrony Financial IPO
Jul 18, 2014 13:03:00 (ET)
By Ted Mann and Michael Calia
General Electric Co. Chief Executive Jeff Immelt's strategy to improve industrial earnings while shrinking his financial operation is gaining traction and yielding results.
On Friday, GE reported a 13% rise in profits and a 3% increase in sales, on the strength of strong earnings from its jet engine and oil and gas equipment businesses. The company also kicked off its planned split-off of its $20 billion North American consumer finance business through an initial public offering.
The IPO sets in motion GE's biggest move to slim down its giant GE Capital business as Mr. Immelt weans the company off of financial earnings, a step that could help boost its share price. Mr. Immelt expects to reduce the share of profits from GE Capital to 25% of the company's total by 2016 from over 40% currently.
To achieve that goal, he is shedding financial assets while trying to spur growth and cut costs in core industrial businesses, like power turbines and locomotives. GE's move to acquire the energy assets of France's Alstom SA for $17 billion, earlier this summer further adds to its industrial heft.
"We are boldly reshaping the company," Mr. Immelt said.
On Friday, GE also began marketing Synchrony Financial, the rechristened consumer finance business, to investors. The company is seeking to raise about $3.1 billion for the business by selling a 15% stake. Synchrony offers retail financing and backs store-branded credit cards at outlets including Wal-Mart, Lowe's and J.C. Penney.
Synchrony set the expected price range of 125 million shares at $23 to $26 each, with the goal of listing at the end of July.
The IPO appears set to be the biggest debut by a U.S. company this year so far, topping the $2.6 billion offering by Ally Financial in April. The stake GE retains in the business will be worth about $17 billion, valuing Synchrony at around $20 billion.
Mr. Immelt said Friday that another key element of his plans was on track: divesting $4 billion of non-core industrial businesses over the course of 2014.
GE hasn't said which businesses it would cut loose, but people familiar with the matter said this week that there is renewed discussion of jettisoning its home appliance unit, which remains profitable but at lower margins than some of GE's other operations. GE Chief Financial Officer Jeff Bornstein declined to comment on the matter.
Overall GE posted earnings of $3.55 billion and revenue improved 3.4% to $36.23 billion. Its industrial businesses posted a 9% increase in profit during the latest period, along with wider margins. GE Capital profits were down 5 percent.
"The environment continues to be generally positive," Mr. Immelt said citing improved rail loadings, better demand for commercial credit, and stronger sales of appliances.
GE shares, which are down 6% so far this year, fell 1% Friday.
Overall equipment orders for the quarter fell in all the industrial segments compared to one year earlier, except for the transportation unit, which ticked up 40% on the strength of new orders for locomotives.
A stagnant U.S. market is slowing performance in GE's healthcare business, which reported flat revenues from a year earlier. CFO Mr. Bornstein said a combination of uncertainty from the implementation of the Affordable Care Act and "increased consumerism" from patients was prompting U.S. hospitals and clinics to hold back from making new orders of heavy medical equipment, like the scanners and X-ray units GE makes.
Mr. Immelt was unfazed, and suggested it was one more reason to embrace the conglomerate model that he has been trying to bulwark.
"I think the good part about GE is we have other segments that will be higher than our original expectations and so that in total we still feel good about the overall framework" of industrial profit growth, he said.
Write to Ted Mann at ted.mann@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
July 18, 2014 13:03 ET (17:03 GMT)
Copyright (c) 2014 Dow Jones & Company, Inc.
$BABA - Alibaba may discount IPO price to avoid Facebook's pitfall
http://fortune.com/2014/07/18/alibaba-may-discount-ipo-price-to-avoid-facebooks-pitfall/
$BABA - Alibaba reportedly planning to go public after Labor Day
http://fortune.com/2014/07/17/alibaba-reportedly-planning-to-go-public-after-labor-day/
$STEM - StemCells, Inc. Announces Closing of $20 Million Offering
1:40 PM ET 7/18/14 | GlobeNewswire
StemCells, Inc. (Nasdaq:STEM), today announced that it has closed its previously announced offering of common stock and short term warrants. The Company sold a total of 11,299,435 units to two well recognized institutional biotechnology investors and received total proceeds, net of offering expenses and placement agent fees, of approximately $18.7 million. Each unit consists of one share of common stock and a warrant to purchase 0.85 of a share of common stock at a price of $1.77 per unit. The warrants will first be exercisable six months from the date of issuance at an initial exercise price of $2.17 per share. The warrants will expire at the close of business on August 17, 2015.
"Two sophisticated investors approached us to provide $20 million of capital based upon the strength of our interim clinical data, and our ongoing translation agenda," said Greg Schiffman, chief financial officer of StemCells, Inc. "Moreover, this transaction was structured with a short term warrant which provides the investors with the potential to provide approximately $20 million in additional capital next year. The proceeds from this financing, combined with the funds from the warrants, should they be exercised, would provide sufficient capital to finance our projected 2015 operating expenditures, by which time we expect to have final data from our Phase I/II clinical programs in spinal cord injury and dry age related macular degeneration and should have initiated controlled proof of concept Phase II clinical programs in both of these indications."
Ascendiant Capital Markets, LLC acted as financial advisor and placement agent for the offering.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company conducted a Phase I/II clinical trial in chronic spinal cord injury in Switzerland, Canada and the United States, and has reported positive interim data for the first eight patients. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD) in the United States. In addition, the Company is pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine (CIRM). StemCells also markets stem cell research products, including media and reagents, under the SC Proven brand. Further information about StemCells is available at http://www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the future business operations of StemCells, Inc. (the "Company"); the Company's expected use of net proceeds; the sufficiency of the proceeds from the offering together with proceeds from the exercise of the warrants, if any, to fund 2015 operating expenditures; and the prospect for continued clinical development of the Company's HuCNS-SC cells in CNS disorders including the prospect of initiating Phase II clinical studies in dry age related macular degeneration and spinal cord injury. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company's HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether the FDA or other applicable regulatory agencies or review boards will permit the Company to continue clinical testing in AMD or spinal cord injury; uncertainties regarding the timing and duration of any clinical trials; uncertainties regarding the Company's ability to recruit the patients required to conduct its clinical trials or to obtain meaningful results; uncertainties regarding the Company's ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainties regarding the Company's manufacturing capabilities given its increasing preclinical and clinical commitments; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in the Company's cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; uncertainties regarding the Company's ability to commercialize a therapeutic product and its ability to successfully compete with other products on the market; and other factors that are described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and in its subsequent reports on Form 10-Q and Form 8-K.
CONTACT: Greg Schiffman
StemCells, Inc.
Chief Financial Officer
(510) 456-4128
Andrea Flynn
Russo Partners
(646) 942-5631
http://media.globenewswire.com/cache/12168/small/7762.jpg
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwOTAwMjgjMTIxNjg=
$OCRX - Ocera Therapeutics Raises $25.2 Million in Public Offering
8:33 AM ET 7/10/14 | GlobeNewswire
Ocera Therapeutics (Nasdaq:OCRX) ("Ocera") today announced that it has priced an underwritten public offering of 4,200,000 shares of its common stock at an offering price of $6.00 per share. The offering will raise gross proceeds to Ocera of $25.2 million before deducting the underwriting discount and other offering expenses. Ocera has also granted the underwriters a 30-day option to purchase up to an additional 630,000 shares of common stock, which would result in additional gross proceeds of $3.78 million, if exercised in full.
Ocera intends to use the proceeds to progress the clinical development programs of OCR-002 and for working capital and other general corporate purposes. The offering is expected to close on July 15, 2014, subject to the satisfaction of customary closing conditions.
Stifel and Cowen and Company acted as joint bookrunning managers for the offering. JMP Securities acted as lead manager.
A shelf registration statement on Form S-3 relating to the shares of common stock to be issued in the offering has been filed with the Securities and Exchange Commission (the "SEC") and declared effective. A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the website of the SEC at www.sec.gov. When available, copies of the final prospectus supplement and accompanying base prospectus relating to the offering may also be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2500, or from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York 11717, Attention: Prospectus Department, or by calling (631) 274-2806, or by faxing (631) 254-7140.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration, or FDA, for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute on chronic liver disease.
Forward-Looking Statements
This press release contains "forward-looking" statements, including, without limitation, statements related to the OCR-002 clinical development program and the proposed uses of proceeds from the offering. These statements are subject to risks and uncertainties that could cause Ocera's actual results to differ materially from those projected and Ocera cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the proposed offering. Additional risks and uncertainties relating to Ocera and its business can be found under the heading "Risk Factors" in Ocera's Annual Report on Form 10-K for the year ended December 31, 2013, as well as other risks detailed in Ocera's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Ocera undertakes no duty to update this information unless required by law.
CONTACT: Michael Byrnes
Ocera Therapeutics, Inc.
Communications@ocerainc.com
650-475-0150
http://media.globenewswire.com/cache/17400/small/20875.png
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwODg4NjgjMTc0MDA=
$LJPC - La Jolla up ahead of expected offering
Jul 11 2014, 12:54 ET | About: La Jolla Pharmaceutical Co. (LJPC)
Shares of thinly-traded La Jolla Pharmaceuticals (LJPC +22.5%) jump on a 5x surge in volume albeit on turnover of only ~500K shares.
The company filed an S-3 on June 27 for a stock-and-warrant offering of $150M.
Wedbush raises its PT to $45 from $34, representing a ~4x rise from today's price. This is a clear signal that it is an underwriter on the issue.
$AA - TODAY, JULY 11, 2014
4:21 PM ET Alcoa Files to Offer up to $5 Billion in Mixed Securities
Dow Jones
IPO Scorecard: Update on Selected Initial Stock Offerings
Jul 11, 2014 15:44:00 (ET)
Company Symbol Percent Currrent Offer IPO Date*
ZS Pharma Inc. ZSPH 64% $29.43 $18.00 18-Jun-14
GoPro Inc. GPRO 63% $39.12 $24.00 26-Jun-14
GlobeImmune Inc. GBIM 46% $14.58 $10.00 2-Jul-14
NextEra Energy Partners LP NEP 40% $34.95 $25.00 27-Jun-14
Kite Pharma Inc. KITE 39% $23.71 $17.00 20-Jun-14
Amphastar Pharmaceuticals Inc. AMPH 30% $9.10 $7.00 25-Jun-14
Viper Energy Partners LP VNOM 26% $32.74 $26.00 18-Jun-14
Ardelyx Inc. ARDX 25% $17.55 $14.00 19-Jun-14
Zafgen Inc. ZFGN 17% $18.74 $16.00 19-Jun-14
Xunlei Ltd. XNET 15% $13.85 $12.00 24-Jun-14
Adeptus Health Inc. ADPT 15% $25.21 $22.00 25-Jun-14
ServiceMaster Global Holdings Inc. SERV 13% $19.17 $17.00 26-Jun-14
Markit Ltd. MRKT 11% $26.59 $24.00 19-Jun-14
Minerva Neurosciences Inc. NERV 11% $6.64 $6.00 1-Jul-14
Performance Sports Group Ltd. PSG 9% $16.90 $15.50 20-Jun-14
Imprivata IMPR 8% $16.25 $15.00 25-Jun-14
Materialise NV MTLS 8% $12.90 $12.00 25-Jun-14
Investar Holding Corp. ISTR 1% $14.20 $14.00 1-Jul-14
Foresight Energy LP FELP 1% $20.10 $20.00 18-Jun-14
The Michaels Cos. Inc. MIK -3% $16.56 $17.00 27-Jun-14
Century Communities Inc. CCS -6% $21.73 $23.00 18-Jun-14
Moko Social Media Ltd. MOKO -8% $6.90 $7.50 27-Jun-14
TCP International Holdings Ltd. TCPI -9% $10.00 $11.00 26-Jun-14
Eclipse Resources Corp. ECR -11% $24.00 $27.00 20-Jun-14
Signal Genetics Inc. SGNL -41% $5.92 $10.00 18-Jun-14
*Date represents first day of trading
(END) Dow Jones Newswires
July 11, 2014 15:44 ET (19:44 GMT)
Copyright (c) 2014 Dow Jones & Company, Inc.
$RVNC - Revance Therapeutics Announces Closing of Its Follow-on Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the closing of its follow-on public offering of 4,600,000 shares of common stock at a public offering price of $30.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 600,000 additional shares of common stock at the same price. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expense payable by Revance Therapeutics will be approximately $131.3 million.
Cowen and Company and Piper Jaffray acted as joint book-running managers for the offering, with BMO Capital Markets and William Blair acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 18, 2014. The offering was made only by means of a prospectus, which is part of the effective registration statement. A copy of the final prospectus relating to the offering may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, Telephone: 800-747-3924, Email: prospectus@pjc.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Revance Therapeutics, Inc.
Revance is a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and therapeutic indications. Revance has developed a platform technology, TransMTS(R), which enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.
CONTACT: Westwicke Partners, Investor Relations
Lynn Pieper
415-202-5678
lynn.pieper@westwicke.com
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwODcwMDEjMjk3NzM=
$AXAS - Abraxas Petroleum Corporation Announces Exercise of Over-Allotment Option and Closing of Public Offering
Abraxas Petroleum Corporation ("Abraxas" or the "Company") (NASDAQ:AXAS) today announced the closing of its public offering of 11,500,000 shares of common stock including 1,500,000 shares sold pursuant to the exercise by the underwriters of their full option to purchase additional shares at a price of $5.00 per share, less applicable underwriting discounts.
The offering was made pursuant to an effective shelf registration statement on Form S-3 previously filed by the Company with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. This offering was made by means of a prospectus supplement and related base prospectus.
Stephens Inc., Canaccord Genuity Inc. and Robert W. Baird & Co. Inc. acted as joint book-runners in the offering. Copies of the preliminary prospectus supplement for the offering may be obtained on the website of the Securities and Exchange Commission (the "SEC"), www.sec.gov, or by contacting Stephens Inc.'s Prospectus Department at Stephens Inc., 111 Center Street, Little Rock, AR 72201, ATTN: Prospectus Department (prospectus@stephens.com) or by telephone at 501-377-2131. Canaccord Genuity Inc., ATTN: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110. Robert W. Baird & Co. Inc., ATTN: Syndicate Department, 777 East Wisconsin Avenue, Milwaukee, WI 53202, or by telephone at 800-792-2473.
Abraxas Petroleum is a San Antonio based crude oil and natural gas exploration and production company with operations across the Rocky Mountain, Permian Basin and Gulf Coast regions of the United States and in the province of Alberta, Canada.
Safe Harbor for forward-looking statements: Statements in this release looking forward in time involve known and unknown risks and uncertainties, which may cause Abraxas Petroleum's actual results in future periods to be materially different from any future performance suggested in this release. Such factors may include, but may not be necessarily limited to, changes in the prices received by Abraxas Petroleum for its crude oil and natural gas. In addition, Abraxas Petroleum's future crude oil and natural gas production is highly dependent upon the Company's level of success in acquiring or finding additional reserves. Further, Abraxas Petroleum operates in an industry sector where the value of securities is highly volatile and may be influenced by economic and other factors beyond the Company's control. In the context of forward-looking information provided for in this release, reference is made to the discussion of risk factors detailed in Abraxas Petroleum's filings with the Securities and Exchange Commission during the past 12 months.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140624006486r1&sid=cmtx6&distro=nx
SOURCE: Abraxas Petroleum Corporation
Abraxas Petroleum Corporation
Geoffrey R. King, 210-490-4788
Vice President and Chief Financial Officer
gking@abraxaspetroleum.com
www.abraxaspetroleum.com
$ASM - Avino Announces At-The-Market Offering of $25 Million
8:01 AM ET 7/7/14 | Marketwire
Avino Silver and Gold Mines Ltd. ("Avino" or "the Company") (TSX VENTURE: ASM) (NYSE MKT: ASM) (FRANKFURT: GV6) today announced that it has filed a prospectus supplement under which it may sell up to US $25,000,000 of its common shares from time to time through Cantor Fitzgerald & Co., as sale agent.
Sales of common shares under the at-the-market offering, if any, would be made by means of ordinary brokers' transactions on the NYSE MKT at market prices or as otherwise agreed with the agents. The Company intends to use the proceeds from any sales of the common shares to acquire and develop the Bralorne mine, advancing the exploration and development of the Avino property including its operations and production, and for working capital.
The common shares to be sold in the at-the-market offering, if any, will be made pursuant to a prospectus supplement to the Company's prospectus, dated July 7, 2014, filed as part of the Company's effective registration statement. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. The at-the-market offering may be made only by means of a prospectus supplement and the related prospectus.
Cantor Fitzgerald & Co. is the sales agent for the at-the-market offering. Copies of the prospectus supplement and accompanying prospectus relating to these securities may be obtained by contacting Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 East 59th Street, New York, New York, 10022, telephone: 212-829-7122.
"We are very excited to have Cantor Fitzgerald working to help Avino reach its goal of becoming a mid-tier producer."
- David Wolfin, President, CEO & Director, Avino Silver & Gold Mines Ltd.
About Avino
Founded in 1968, Avino's mission is to create shareholder value through profitable organic growth at the historic Avino property near Durango, Mexico, and the strategic acquisition of mineral exploration and mining properties. We are committed to managing all business activities in an environmentally responsible and cost-effective manner, while contributing to the well-being of the communities in which we operate.
ON BEHALF OF THE BOARD
David Wolfin, President & CEO
Avino Silver & Gold Mines Ltd.
Safe Harbor Statement - This news release contains "forward-looking information" and "forward-looking statements" (together, the "forward looking statements") within the meaning of applicable securities laws and the United States Private Securities Litigation Reform Act of 1995, including our intent to acquire and develop the Bralorne mine, belief as to the extent and timing of various studies including the PEA, and exploration results, the potential tonnage, grades and content of deposits, timing and establishment and extent of resources estimates. These forward-looking statements are made as of the date of this news release and the dates of technical reports, as applicable. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated in or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. While we have based these forward-looking statements on our expectations about future events as at the date that such statements were prepared, the statements are not a guarantee that such future events will occur and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements.
Such factors and assumptions include, among others, the effects of general economic conditions, the price of gold, silver and copper, changing foreign exchange rates and actions by government authorities, uncertainties associated with legal proceedings and negotiations and misjudgments in the course of preparing forward-looking information. In addition, there are known and unknown risk factors which could cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Known risk factors include risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; fluctuations in metal prices; title matters; uncertainties and risks related to carrying on business in foreign countries; environmental liability claims and insurance; reliance on key personnel; the potential for conflicts of interest among certain of our officers, directors or promoters of with certain other projects; the absence of dividends; currency fluctuations; competition; dilution; the volatility of the our common share price and volume; tax consequences to U.S. investors; and other risks and uncertainties as disclosed in our filings with the US Securities and Exchange Commission. Although we have attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. We are under no obligation to update or alter any forward-looking statements except as required under applicable securities laws.
Cautionary Note to United States Investors - The information contained herein and incorporated by reference herein has been prepared in accordance with the requirements of Canadian securities laws, which differ from the requirements of United States securities laws. In particular, the term "resource" does not equate to the term "reserve". The Securities Exchange Commission's (the "SEC") disclosure standards normally do not permit the inclusion of information concerning "measured mineral resources", "indicated mineral resources" or "inferred mineral resources" or other descriptions of the amount of mineralization in mineral deposits that do not constitute "reserves" by SEC standards, unless such information is required to be disclosed by the law of the Company's jurisdiction of incorporation or of a jurisdiction in which its securities are traded. U.S. investors should also understand that "inferred mineral resources" have a great amount of uncertainty as to their existence and great uncertainty as to their economic and legal feasibility. Disclosure of "contained ounces" is permitted disclosure under Canadian regulations; however, the SEC normally only permits issuers to report mineralization that does not constitute "reserves" by SEC standards as in place tonnage and grade without reference to unit measures.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Avino Silver & Gold Mines Ltd.
David Wolfin
President & CEO
604.682.3701
604.682.3600 (FAX)
ir@avino.com
www.avino.com
SOURCE: Avino Silver & Gold Mines Ltd.
$TE - TECO Energy Announces Pricing of Public Offering of Common Stock
8:23 PM ET 7/1/14 | BusinessWire
TECO Energy, Inc. (NYSE:TE) today reported that it has entered into an underwriting agreement for the sale by the company of 15.5 million primary shares of its common stock pursuant to an effective shelf registration statement at a price to the public of $18.10 per share through underwriters led by Morgan Stanley, Citigroup and JP Morgan as joint bookrunning managers. The offering is expected to close on or about July 8, 2014, subject to customary closing conditions.
Net proceeds from the sale are expected to be about $271 million after expenses and will be used to fund, in part, TECO Energy's acquisition of New Mexico Gas Co. and for general corporate purposes. TECO Energy has also granted the underwriters an option for a period of 30 days to purchase an additional 2,325,000 shares of common stock on the same terms and conditions.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any state or jurisdiction. The offering is being made only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement. A copy of the preliminary prospectus supplement and accompanying prospectus relating to this offering may be obtained from the offices of Morgan Stanley, Prospectus Department, 180 Varick Street 2nd Floor, New York, New York 10014, Citigroup Global Markets, Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717. An electronic copy of the final prospectus supplement and accompanying prospectus will be available from the Securities and Exchange Commission's web site at www.sec.gov.
TECO Energy Inc. (NYSE: TE) is an energy-related holding company. Its principal subsidiary, Tampa Electric Co., is a regulated utility in Florida with both electric and gas divisions (Tampa Electric and Peoples Gas System). Tampa Electric serves more than 700,000 customers in West Central Florida, and Peoples Gas serves more than 350,000 customers in most of Florida's major metropolitan areas and beyond. Other TECO Energy subsidiaries include TECO Coal, which owns and operates coal-production facilities in Kentucky, Tennessee and Virginia.
NOTE: This press release contains forward-looking statements about the anticipated completion of the public offering and the company's intentions to use the net proceeds from the offering, including the proposed acquisition of New Mexico Gas Co., which are all subject to the inherent uncertainties in predicting future results and conditions. Additional information is contained under "Risk Factors" in TECO Energy, Inc.'s Annual Report on Form 10-K for the period ended December 31, 2013, and in the prospectus supplement related to the offering.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140701006651r1&sid=cmtx6&distro=nx
SOURCE: TECO Energy, Inc.
TECO Energy, Inc.
News Media:
Cherie Jacobs, 813-228-4945
or
Investor Relations:
Mark Kane, 813-228-1772
$GPRO - GoPro Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
4:30 PM ET 7/1/14 | PR Newswire
GoPro, Inc. (NASDAQ: GPRO) today announced the closing of its initial public offering of Class A common stock and the full exercise of the underwriters' option to purchase 2,670,000 additional shares. GoPro sold 8,900,000 shares and the selling stockholders sold 11,570,000 shares, including the shares sold upon exercise of the underwriters' option to purchase additional shares.
J.P. Morgan, Citigroup, and Barclays are acting as lead joint book-running managers for the offering. Allen & Company, Stifel, Baird, MCS Capital Markets, Piper Jaffray, and Raymond James are acting as co-managers for the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 25, 2014. This offering was made solely by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by phone at (866) 803-9204; from Citigroup Global Markets Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by phone at (800) 831-9146; or from Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by phone at (888) 603-5847.
SOURCE GoPro, Inc.
$GPRO - $49.50 +8.95 (+22.07%) unreal!!!
$BABA - ALIBABA WILL LIST WITH NYSE AND UNDER TICKER SYMBOL $BABA
$GPRO - GoPro doesn't disappoint in public debut
11:46 AM ET 6/26/14 | MarketWatch
By Rex Crum, MarketWatch
SAN FRANCISCO (MarketWatch) -- While much of the tech sector was in the red Thursday, the surge in shares of digital-sport camera maker GoPro Inc. that garnered much of the market's attention as the company made its public debut.
GoPro (GPRO) shares surged more than 30% to $31.35 as the company went public in an IPO that opened at $24 a share. GoPro sold 17.8 million shares and raised almost $430 million in its IPO.
Zulily (ZU) added to its prior-day's gains by rising 2.4% to $40.84 after RBC Capital Markets analyst Mark Mahaney raised his rating on the online retailer of clothing for children and women to outperform from sector perform. Mahaney cited high customer-satisfaction data and expansion beyond children's apparel among the reasons for his upgrade. Mahaney set a price target of $50-a-share price on Zulily's stock.
It was the second upgrade in as many days for Zulily. On Wednesday, Goldman Sachs analyst Debra Schwartz raised her rating on Zulily to buy from neutral and lifted her price target to $50 a share from $47.
Other mild gains came from Twitter Inc. (TWTR), Groupon Inc. (GRPN), Yahoo Inc. (YHOO) and Hewlett-Packard Co. (HPQ)
The tech-heavy Nasdaq Composite Index (RIXF) fell 16 points to 4,364, while the Philadelphia Semiconductor Index (SOX) was off by almost 1%.
More must-read news from MarketWatch:
Four things GoPro must do to succeed
Here's your note to skip work and watch the U.S.-Germany World Cup game
China pulling plug on U.S. mainframe makers
-Rex Crum; 415-439-6400; AskNewswires@dowjones.com
> Dow Jones Newswires
June 26, 2014 11:46 ET (15:46 GMT)
Copyright (c) 2014 Dow Jones & Company, Inc.
$GPRO - GoPro shares climb more than 27% in IPO debut
11:46 AM ET 6/26/14 | MarketWatch
SAN FRANCISCO (MarketWatch) -- GoPro Inc. (GPRO) shares surged more than 28% to $30.73 as the maker of the popular sport-digital cameras made its debut as a public company Thursday. GoPro shares climbed by more than $6 from the $24-a-share price that the company set late Wednesday. GoPro sold 17.8 million shares in its IPO and raised $427 million with the offering.
-Rex Crum; 415-439-6400; AskNewswires@dowjones.com
> Dow Jones Newswires
June 26, 2014 11:46 ET (15:46 GMT)
Copyright (c) 2014 Dow Jones & Company, Inc.
$GWPH - GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Totaling Approximately $169.8 Million on the NASDAQ Global Market and Full Exercise of Underwriters' Option to Purchase Additional ADSs
11:15 AM ET 6/25/14 | GlobeNewswire
GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced offering on the NASDAQ Global Market by GW and certain of its selling shareholders of 1,700,000 American Depositary Shares (ADSs) and the full exercise by the underwriters of their option to purchase 255,000 additional ADSs from GW at a price of $86.83 per ADS. The ADSs sold in the offering consisted of 1,455,000 ADSs sold by the Company, and 500,000 ADSs sold by the selling shareholders, and raised gross proceeds to GW of $126.3 million (before deducting underwriting discount, commissions and offering expenses). GW did not receive any proceeds from the sale of ADSs by the selling shareholders in this offering.
Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as joint book-running managers for the offering. Piper Jaffray & Co. acted as lead manager.
The ADSs described above were offered by GW and the selling shareholders pursuant to a shelf registration statement filed by GW with the Securities and Exchange Commission ("SEC") that became automatically effective on May 7, 2014. The offering of the ADSs was made only by means of a prospectus and prospectus supplement. You may obtain these documents on the SEC's website at http://www.sec.gov. Alternatively, the prospectus and prospectus supplement may be obtained from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; BofA Merrill Lynch, 222 Broadway, New York, NY 10038, attention: Prospectus Department, email: dg.prospectus_requests@baml.com; Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department; or from Piper Jaffray, Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.
For readers in the European Economic Area:
In any EEA Member State that has implemented the Prospectus Directive, this communication is only addressed to and directed at qualified investors in that Member State within the meaning of the Prospectus Directive. The term "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in each relevant Member State), together with any relevant implementing measure in the relevant Member State.
For readers in the United Kingdom:
This communication, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of s21 Financial Services and Markets Act 2000 as amended) in connection with the securities which are the subject of the offering described in this press release or otherwise, is being directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments who fall within Article 19(5) ("Investment professionals") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) certain high value persons and entities who fall within Article 49(2)(a) to (d) ("High net worth companies, unincorporated associations etc") of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as "relevant persons"). The ADSs are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.
Forward-looking statements
This news release may contain forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding the development and regulatory clearance of the GW's products. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex(R), Epidiolex(R) and other products and product candidates by consumer and medical professionals. A further list and description of other risks and uncertainties associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including its shelf registration statement and the documents incorporated by reference therein. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Enquiries:
View data
GW Pharmaceuticals plc (Today) +44 20 3727 1000 Justin Gover, Chief Executive Officer (Thereafter) + 44 1980 557000 Stephen Schultz, VP Investor Relations (US) 917 280 2424 / 401 500 6570 FTI Consulting (Media Enquiries) Ben Atwell / Simon Conway / John Dineen (UK) + 44 20 3727 1000 Robert Stanislaro (US) 212 850 5657 Trout Group, LLC (US investor relations) Todd James / Chad Rubin 646 378 2900
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwODcwMTMjMjYxNTM=
$KONA - Kona Grill Announces Completion of Public Offering and Exercise in Full of Option to Purchase Additional Shares of Common Stock
1:35 PM ET 6/25/14 | Marketwire
Kona Grill, Inc. (NASDAQ: KONA), an American grill and sushi bar, today announced the completion of an underwritten public offering of 2,645,000 shares of its common stock at a public offering price of $18.50 per share. An aggregate of 2,345,000 of these shares were sold by the Company, which included 345,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, and 300,000 shares were sold by certain selling stockholders. The offering closed on June 25, 2014. The gross proceeds to the Company from this offering were $43.4 million, before deducting the underwriting discount and other estimated offering expenses.
The Company intends to use the net proceeds from its sale of shares in the offering for new unit expansion, remodel and maintenance capital expenditures and for working capital and other general corporate purposes.
KeyBanc Capital Markets and Raymond James served as joint book-running managers in the offering. Feltl & Company, Janney Montgomery Scott, Lake Street Capital Markets and Wunderlich Securities served as co-managers.
This offering was made pursuant to a registration statement previously filed with the Securities and Exchange Commission (the "SEC"), which was declared effective on June 19, 2014. A final prospectus related to the offering was filed with the SEC and is available on the SEC's website located at www.sec.gov. Copies of the final prospectus may also be obtained by contacting KeyBanc Capital Markets, Attention: Equity Syndicate, 127 Public Square, 4th Floor, Cleveland, Ohio 44114 or by telephone at (800) 859-1783; or Raymond James, Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by email to prospectus@raymondjames.com or by telephone at (800) 248-8863.
This press release shall not constitute an offer to sell or the solicitation of an offer to purchase, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Kona Grill Kona Grill (NASDAQ: KONA) features American favorites with an international influence and award-winning sushi in a casually elegant atmosphere. Kona Grill owns and operates 27 restaurants, guided by a passion for quality food and personal service. Restaurants are currently located in 17 states: Arizona (Chandler, Gilbert, Phoenix, Scottsdale); Colorado (Denver); Connecticut (Stamford); Florida (Tampa); Idaho (Boise); Illinois (Lincolnshire, Oak Brook); Indiana (Carmel); Louisiana (Baton Rouge); Maryland (Baltimore); Michigan (Troy); Minnesota (Eden Prairie); Missouri (Kansas City); Nebraska (Omaha); New Jersey (Woodbridge); Nevada (Las Vegas); Texas (Austin, Dallas, El Paso, Fort Worth, Houston, San Antonio, The Woodlands); Virginia (Richmond). For more information, visit www.konagrill.com.
Investor Relations Contact:
Liolios Group, Inc.
Cody Slach
Tel 1-949-574-3860
Email Contact
SOURCE: Kona Grill, Inc.
$GWPH - $92.24 +4.22 (+4.79%)
$GWPH - $90.62 +3.79 (+4.36%)
$AXAS - Abraxas Petroleum Announces Pricing of Offering
6:51 PM ET 6/18/14 | BusinessWire
Abraxas Petroleum Corporation (NASDAQ:AXAS) ("Abraxas Petroleum" or the "Company") today announced that it has priced its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share. Abraxas Petroleum has granted the underwriters a 30-day option to purchase up to 1,500,000 additional shares of common stock.
The offering is expected to settle and close on or about June 24, 2014, subject to customary closing conditions. The Company intends to use the net proceeds from this offering of approximately $47.0 million (and the net proceeds from any exercise of the underwriters' option to purchase additional shares of common stock) to accelerate its 2014 drilling program on both its Bakken and Eagle Ford properties, acquire additional leased acreage primarily in the Eagle Ford, repay indebtedness outstanding under its credit facility and for general corporate purposes.
Stephens Inc., Canaccord Genuity Inc. and Robert W. Baird & Co. Inc. are acting as joint book-runners in the offering. Copies of the preliminary prospectus supplement for the offering may be obtained on the website of the Securities and Exchange Commission (the "SEC"), www.sec.gov, or by contacting Stephens Inc.'s Prospectus Department at Stephens Inc., 111 Center Street, Little Rock, AR 72201, ATTN: Prospectus Department (prospectus@stephens.com) or by telephone at 501-377-2131. Canaccord Genuity Inc., ATTN: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110. Robert W. Baird & Co. Inc., ATTN: Syndicate Department, 777 East Wisconsin Avenue, Milwaukee, WI 53202, or by telephone at 800-792-2473.
The offering is being made pursuant to an effective shelf registration statement on Form S-3 previously filed by the Company with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. This offering is being made by means of a prospectus supplement and related base prospectus.
Abraxas Petroleum is a San Antonio based crude oil and natural gas exploration and production company with operations across the Rocky Mountain, Permian Basin and Gulf Coast regions of the United States and in the province of Alberta, Canada.
Safe Harbor for forward-looking statements: Statements in this release looking forward in time involve known and unknown risks and uncertainties, which may cause Abraxas Petroleum's actual results in future periods to be materially different from any future performance suggested in this release. Such factors may include, but may not be necessarily limited to, changes in the prices received by Abraxas Petroleum for its crude oil and natural gas. In addition, Abraxas Petroleum's future crude oil and natural gas production is highly dependent upon the Company's level of success in acquiring or finding additional reserves. Further, Abraxas Petroleum operates in an industry sector where the value of securities is highly volatile and may be influenced by economic and other factors beyond the Company's control. In the context of forward-looking information provided for in this release, reference is made to the discussion of risk factors detailed in Abraxas Petroleum's filings with the Securities and Exchange Commission during the past 12 months.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140618006616r1&sid=cmtx6&distro=nx
SOURCE: Abraxas Petroleum Corporation
Abraxas Petroleum Corporation
Geoffrey R. King, 210-490-4788
Vice President and Chief Financial Officer
gking@abraxaspetroleum.com
www.abraxaspetroleum.com
$AXAS - Abraxas Launches Common Stock Offering
4:42 PM ET 6/12/14 | BusinessWire
Abraxas Petroleum Corporation (NASDAQ:AXAS) is pleased to announce the commencement of an underwritten public offering of 10,000,000 shares of its common stock, subject to market and other conditions. The underwriters will have an option to purchase up to an additional 1,500,000 shares from Abraxas. Abraxas intends to use the net proceeds from this offering for general corporate purposes, which includes an acceleration of the company's Eagle Ford drilling program.
Stephens Inc., Canaccord Genuity Inc. and Robert W. Baird & Co. Inc. are acting as joint book-runners in the offering. Copies of the preliminary prospectus supplement for the offering may be obtained on the website of the Securities and Exchange Commission, www.sec.gov, or by contacting Stephens Inc.'s Prospectus Department at Stephens Inc., 111 Center Street, Little Rock, AR 72201, ATTN: Prospectus Department (prospectus@stephens.com) or by telephone at 501-377-2131. Canaccord Genuity Inc., ATTN: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110. Robert W. Baird & Co. Inc., Syndicate Department, 777 East Wisconsin Avenue, Milwaukee, Wisconsin 53202, or by telephone at 800-792-2473.
The common stock will be issued and sold pursuant to an effective automatic shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. This offering may only be made by means of a prospectus supplement and related base prospectus.
Abraxas Petroleum Corporation is a San Antonio based crude oil and natural gas exploration and production company with operations across the Rocky Mountain, Permian Basin and onshore Gulf Coast regions of the United States and in the province of Alberta, Canada.
Safe Harbor for forward-looking statements: Statements in this release looking forward in time involve known and unknown risks and uncertainties, which may cause Abraxas' actual results in future periods to be materially different from any future performance suggested in this release. Such factors may include, but may not be necessarily limited to, changes in the prices received by Abraxas for crude oil and natural gas. In addition, Abraxas' future crude oil and natural gas production is highly dependent upon Abraxas' level of success in acquiring or finding additional reserves. Further, Abraxas operates in an industry sector where the value of securities is highly volatile and may be influenced by economic and other factors beyond Abraxas' control. In the context of forward-looking information provided for in this release, reference is made to the discussion of risk factors detailed in Abraxas' filings with the Securities and Exchange Commission during the past 12 months.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140612006390r1&sid=cmtx6&distro=nx
SOURCE: Abraxas Petroleum Corporation
Abraxas Petroleum Corporation
Geoffrey King, 210-490-4788
Vice President - Chief Financial Officer
gking@abraxaspetroleum.com
www.abraxaspetroleum.com
$KONA - Why Did KONA Make A Public Offer?
KONA expects to use its holistic proceeds, obtained by selling out its shares in the discourse of this public offering, in order to remodel and maintain its sumptuous capital expenses. Besides, the company expects to work towards developing a brand new unit – expanding its outreach and business unit functionalities, and generate a larger gamut of options to use its increasing working capital for a myriad of its general corporate purposes. The authorities have corroborated that the premise of the IPO shall be vested rightfully, solely with KONA. Kona Grill Inc (NASDAQ:KONA) should not solicit or offer to duly sell out this public offering or its securities in provinces and states, or under certain jurisdictions, where such a solicitation, sale or offer is deemed to be unlawful, provided the company has attained prior qualifications.
- See more at: http://basicsmedia.com/kona-grill-inc-nasdaqkona-proposes-an-ipo-hopes-to-build-on-its-credible-gains-in-fy14-15-9807#sthash.ZOvcrfIw.dpuf
$RVNC - Revance Therapeutics Announces Pricing of Its Public Offering of Common Stock
10:05 PM ET 6/18/14 | GlobeNewswire
Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $30.50 per share pursuant to a registration statement filed with the Securities and Exchange Commission (SEC). All of the shares in the offering are to be sold by Revance. In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 600,000 shares from Revance. The offering is expected to close on June 24, 2014, subject to customary closing conditions.
Cowen and Company and Piper Jaffray are acting as joint book-running managers for the offering, with BMO Capital Markets and William Blair acting as co-managers.
The offering will be made only by means of a prospectus, copies of which may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, Telephone: 800-747-3924, Email: prospectus@pjc.com.
A registration statement relating to these securities has been filed with the SEC and was declared effective by the SEC on June 18, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Revance Therapeutics, Inc.
Revance is a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and therapeutic indications. Revance has developed a platform technology, TransMTS(R), which enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Revance's expectations regarding the completion of the public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not Revance will be able to raise capital through the sale of shares of common stock, the final terms of the public offering, market and other conditions, the satisfaction of customary closing conditions related to the public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Revance will be able to complete the public offering on the anticipated terms, or at all. Revance will need to raise additional capital to fund its operations and may be unable to raise capital when needed, which would force Revance to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the public offering, Revance and its business can be found under the heading "Risk Factors" in the prospectus included in Revance's Registration Statement on Form S-1 (File No. 333-196582), initially filed with the SEC on June 6, 2014, as amended. Revance expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
CONTACT: Westwicke Partners, Investor Relations
Lynn Pieper
415-202-5678
lynn.pieper@westwicke.com
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwODYzNDYjMjk3NzM=
$GWPH - GW Pharmaceuticals Announces Proposed Public Offering of ADSs
LONDON, June 17, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it and certain of its shareholders intend to sell, subject to market and other conditions, 1.7 million American Depositary Shares ("ADSs") representing ordinary shares of GW on the NASDAQ Global Market in an underwritten U.S. public offering. GW will grant the underwriters a 30-day option to purchase up to an additional 255,000 ADSs at the offering price. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The price for the offering has not yet been determined.
Morgan Stanley, BofA Merrill Lynch and Cowen and Company are acting as joint book-running managers for the offering. Piper Jaffray is acting as lead manager.
The ADSs described above are being offered by GW and the selling shareholders pursuant to a shelf registration statement filed by GW with the Securities and Exchange Commission ("SEC") that became automatically effective on May 7, 2014. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; BofA Merrill Lynch, 222 Broadway, New York, NY 10038, attention: Prospectus Department, email: dg.prospectus_requests@baml.com; or from Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department; or from Piper Jaffray, Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
There will be no offer of ADSs to the public in the UK. This press release is not directed to, or intended for distribution or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.
The distribution of this press release into jurisdictions other than the UK may be restricted by law. Persons into whose possession this announcement come should inform themselves about and observe any such restrictions.
For readers in the European Economic Area
In any EEA Member State that has implemented the Prospectus Directive, this communication is only addressed to and directed at qualified investors in that Member State within the meaning of the Prospectus Directive. The term "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in each relevant Member State), together with any relevant implementing measure in the relevant Member State.
For readers in the United Kingdom
This communication, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of s21 Financial Services and Markets Act 2000 as amended) in connection with the securities which are the subject of the offering described in this press release or otherwise, is being directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments who fall within Article 19(5) ("Investment professionals") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) certain high value persons and entities who fall within Article 49(2)(a) to (d) ("High net worth companies, unincorporated associations etc") of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as "relevant persons"). The ADSs are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.
Forward-looking statements
This news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including statements regarding the timing of and potential listing of American Depository Shares on the NASDAQ Global Market, the proposed timing of such offering and development and regulatory clearance of the GW's products. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex®, Epidiolex®and other products and product candidates by consumer and medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including its shelf registration statement and the documents incorporated by reference therein. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Enquiries:
GW Pharmaceuticals plc (Today) +44 20 3727 1000
Justin Gover, Chief Executive Officer (Thereafter) + 44 1980 557000
Stephen Schultz, VP Investor Relations (US) 917 280 2424 / 401 500 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen (UK) + 44 20 3727 1000
Robert Stanislaro (US) 212 850 5657
Trout Group, LLC (US investor relations)
Todd James / Chad Rubin 646 378 2900
$KND - Kindred Offers $534 Million Bid for Gentiva -- Update
6:57 PM ET 6/16/14 | Dow Jones
By Tess Stynes
Kindred Healthcare Inc. raised its takeover bid for Gentiva Health Services Inc. to about $534 million in cash, which it plans to take directly to shareholders starting Tuesday.
Long-term care provider Kindred is now offering $14.50 a share for Gentiva, which provides skilled nursing, physical, occupational, speech and neuro rehabilitation therapies.
A representative for Gentiva wasn't immediately available for comment.
In late May, Gentiva disclosed a poison-pill plan with a 15% trigger. Such plans discourage unwanted suitors by threatening to dilute their stakes. In response to the implementation of the plan, Kindred said that if its takeover offer, which requires a majority of shares be tendered, isn't completed it plans to amend its offer to the purchase 14.9% of Gentiva's stock if the company refuses to redeem the poison pill. Kindred said that if the offer was amended, it would be extended by at least 10 business days to allow holders to decide whether or not to participate.
The move would make Kindred Gentiva's biggest shareholder. In a regulatory filing, Kindred says it expects it would pay about $80 million for the 14.9% stake.
However, the company added that it would strongly prefer a negotiated cash-and-stock transaction.
"Although Gentiva's board has put in place a poison pill, we are moving forward with an all-cash tender offer to demonstrate our commitment to completing this transaction and to provide Gentiva shareholders with an opportunity to make their collective voice heard," Kindred Chief Executive Paul J. Diaz said Monday. "We hope the board and management team of Gentiva view today's actions as tangible evidence of our determination to seeing this process through."
Kindred, which affirmed its 2014 guidance, also said it plans to offer at least nine million shares to raise funds for the proposed acquisition of Gentiva. If the planned takeover isn't completed, Kindred said it would use the funds toward other potential acquisitions or for other purposes including paying down its debt. Further details weren't provided.
As of May 31, Kindred had roughly 54.8 million shares outstanding.
Including preferred share purchase rights, the equity value of the deal is roughly $573 million. Including the assumption of debt, the offer is valued at roughly $1.7 billion.
Last month, Gentiva rejected Kindred's previous cash-and-stock offer, valued at $14 a share at that time. Including debt assumption, the previous offer was valued at about $1.6 billion. Gentiva then said Kindred's offer undervalued the company and its prospects for growth.
Gentiva shares rose 3.9% to $14.54 in recent after-hours trading, while Kindred shares fell 1.6% to $25.34.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
> Dow Jones Newswires
June 16, 2014 18:57 ET (22:57 GMT)
Copyright (c) 2014 Dow Jones & Company, Inc.
$KND - Kindred Healthcare Launches Equity Offering
LOUISVILLE, Ky.--(BUSINESS WIRE)--June 16, 2014--
Kindred Healthcare, Inc. ("Kindred" or "the Company") (NYSE:KND) today announced that it has launched an underwritten public offering ("the Offering") for an aggregate of 9,000,000 shares of Kindred common stock. The Company intends to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of Kindred common stock. Citigroup and Morgan Stanley & Co. LLC are acting as the joint book-running managers for the Offering.
Kindred intends to use the net proceeds from the Offering to finance potential acquisitions or for general corporate purposes, including paying down the Company's existing indebtedness.
This press release is neither an offer to sell nor a solicitation of an offer to buy any of the common stock or any other security of Kindred, nor shall there be any sale of the common stock or any other security of Kindred in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
The Offering is being made pursuant to an effective shelf registration statement that has been filed with the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement and the accompanying prospectus related to the Offering have been filed with the SEC and are available on the SEC website. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the Offering may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by phone at 800-831-9146 or by email at BATProspectusdept@citi.com, and Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, prospectus@morganstanley.com.
Conference Call and Additional Presentation Materials
Kindred's management team will discuss this announcement in a presentation to analysts and investors today at 5:00 p.m. (Eastern Time). Interested parties can listen to the presentation by dialing (888) 802-8577 (U.S.) or (404) 665-9928 (International), conference code 61670302. A webcast of the presentation will be made available on the Company's website at www.kindredhealthcare.com. The presentation will feature accompanying slides, which can be accessed through the Investors section of the Company's website.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding the Company's ability to complete the Offering, the Company's anticipated use of proceeds from the Offering, the Company's proposed acquisition, and statements containing the words such as "anticipate," "approximate," "believe," "plan," "estimate," "expect," "project," "could," "would," "should," "will," "intend," "may," "potential," "upside," and other similar expressions. Statements in this press release that are not historical facts are forward-looking statements that are estimates reflecting the best judgment of the Company based upon currently available information.
Such forward-looking statements are inherently uncertain, and stockholders and other potential investors must recognize that actual results may differ materially from the Company's expectations as a result of a variety of factors, including, without limitation, those set forth in the Company's Annual Report on Form 10-K and in its reports on Forms 10-Q and 8-K. Such forward-looking statements are based upon management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the Company is unable to predict or control, that may cause the Company's actual results, performance or plans to differ materially from any future results, performance or plans expressed or implied by such forward-looking statements. These statements involve risks, uncertainties and other factors detailed from time to time in the Company's filings with the SEC.
Many of these factors are beyond the Company's control. The Company cautions investors that any forward-looking statements made by the Company are not guarantees of future performance. The Company disclaims any obligation to update any such factors or to announce publicly the results of any revisions to any of the forward-looking statements to reflect future events or developments.
About Kindred Healthcare
Kindred Healthcare, Inc., a top-150 private employer in the United States, is a FORTUNE 500 healthcare services company based in Louisville, Kentucky with annual revenues of $5 billion and approximately 63,000 employees in 47 states. At March 31, 2014, Ki ndred through its subsidiaries provided healthcare services in 2,313 locations, including 100 transitional care hospitals, five inpatient rehabilitation hospitals, 99 nursing centers, 22 sub-acute units, 157 Kindred at Home hospice, home health and non-medical home care locations, 105 inpatient rehabilitation units (hospital-based) and a contract rehabilitation services business, RehabCare, which served 1,825 non-affiliated facilities. Ranked as one of Fortune magazine's Most Admired Healthcare Companies for six years in a row, Kindred's mission is to promote healing, provide hope, preserve dignity and produce value for each patient, resident, family member, customer, employee and shareholder we serve. For more information, go to www.kindredhealthcare.com.
CONTACT: Media
Kindred Healthcare, Inc.
Susan Moss, 502-596-7296
Senior Vice President, Marketing and Communications
or
Joele Frank, Wilkinson Brimmer Katcher
Andy Brimmer / Andrew Siegel, 212-355-4449
or
Investors and Analysts
Kindred Healthcare, Inc.
Hank Robinson, 502-596-7732
Senior Vice President, Tax and Treasurer
SOURCE: Kindred Healthcare, Inc.
Copyright Business Wire 2014
Access Investor Kit for Kindred Healthcare, Inc.
Visit http://www.companyspotlight.com/partner?cp_code=A591&isin=US4945801037
$RVNC - Revance Therapeutics Announces Proposed Public Offering of Common Stock
4:05 PM ET 6/16/14 | GlobeNewswire
Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced a proposed underwritten public offering of 3,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission (SEC). Revance expects to grant the underwriters a 30-day option to acquire an additional 450,000 shares. All of the shares in the offering are to be sold by Revance. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Cowen and Company, LLC and Piper Jaffray & Co. are acting as joint book-running managers for the proposed offering, with BMO Capital Markets Corp. and William Blair & Company, L.L.C. acting as co-managers.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the proposed public offering may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, Telephone: 800-747-3924, Email: prospectus@pjc.com.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Revance Therapeutics, Inc.
Revance is a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and therapeutic indications. Revance has developed a platform technology, TransMTS(R), which enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Revance's expectations regarding the completion of the proposed public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not Revance will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Revance will be able to complete the proposed public offering on the anticipated terms, or at all. Revance will need to raise additional capital to fund its operations and may be unable to raise capital when needed, which would force Revance to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the proposed offering, Revance and its business can be found under the heading "Risk Factors" in the prospectus included in Revance's Registration Statement on Form S-1 (File No. 333-196582), initially filed with the SEC on June 6, 2014. Revance expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
CONTACT: Westwicke Partners, Investor Relations
Lynn Pieper
415-202-5678
lynn.pieper@westwicke.com
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwODU5MjYjMjk3NzM=
$KONA - Kona Grill Announces Proposed Public Offering of Common Stock
4:18 PM ET 6/16/14 | Marketwire
Kona Grill, Inc. (NASDAQ: KONA), an American grill and sushi bar, today announced that it is offering to sell 2,000,000 shares of its common stock in an underwritten public offering. In addition, selling stockholders are offering to sell an additional 300,000 shares in the offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional 345,000 shares of common stock in the offering.
The Company intends to use the net proceeds from its sale of shares in the public offering for new unit expansion, remodel and maintenance capital expenditures and for working capital and other general corporate purposes.
KeyBanc Capital Markets and Raymond James are serving as joint book-running managers. Feltl & Company, Janney Montgomery Scott, Lake Street Capital Markets and Wunderlich Securities are serving as co-managers.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. A copy of the preliminary prospectus relating to this offering may be obtained by contacting KeyBanc Capital Markets, Attention: Equity Syndicate, 127 Public Square, 4th Floor, Cleveland, Ohio 44114 or by telephone at (800) 859-1783; or Raymond James, Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by email to prospectus@raymondjames.com or by telephone at (800) 248-8863.
This press release shall not constitute an offer to sell or the solicitation of an offer to purchase, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Kona Grill Kona Grill (NASDAQ: KONA) features American favorites with an international influence and award-winning sushi in a casually elegant atmosphere. Kona Grill owns and operates 26 restaurants, guided by a passion for quality food and personal service. Restaurants are currently located in 17 states: Arizona (Chandler, Gilbert, Phoenix, Scottsdale); Colorado (Denver); Connecticut (Stamford); Florida (Tampa); Idaho (Boise); Illinois (Lincolnshire, Oak Brook); Indiana (Carmel); Louisiana (Baton Rouge); Maryland (Baltimore); Michigan (Troy); Minnesota (Eden Prairie); Missouri (Kansas City); Nebraska (Omaha); New Jersey (Woodbridge); Nevada (Las Vegas); Texas (Austin, Dallas, Fort Worth, Houston, San Antonio, The Woodlands); Virginia (Richmond). For more information, visit www.konagrill.com.
Forward-Looking Statements Except for the historical information contained in this news release, the matters addressed are forward-looking statements. Forward-looking statements, written, oral or otherwise made, represent the Company's expectation or belief concerning future events. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of the Company's strategies, intentions or plans, are also forward-looking statements. Such statements reflect management's current views with respect to future events and are subject to risks and uncertainties, both known and unknown. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond the Company's control. Investors are referred to the full discussion of risks and uncertainties as included in the Company's filings with the Securities and Exchange Commission.
Investor Relations Contact:
Liolios Group, Inc.
Cody Slach
Tel 1-949-574-3860
Email Contact
SOURCE: Kona Grill, Inc.
GoDaddy Inc web hosting company files for IPO of up to US$100-million
http://business.financialpost.com/2014/06/09/godaddy-inc-web-hosting-company-files-for-ipo-of-up-to-us100-million/
GoDaddy initiates IPO
http://www.indiantelevision.com/iworld/e-commerce/godaddy-initiates-ipo-140611
$NVAX - TODAY, JUNE 6, 2014
3:16 AM ET Novavax prices 25 mln shares of common stock at $4.00 per share
Briefing.com
$NVAX - Novavax Announces Proposed Public Offering of Common Stock
4:40 PM ET 6/4/14 | GlobeNewswire
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer to sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering. As part of this offering Novavax, Inc. intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of its common stock. The success, the size and the terms of this offering cannot be guaranteed.
Citigroup and JP Morgan are acting as joint book-running managers of the offering.
All shares being offered are to be sold by Novavax, Inc., with the net proceeds from the offering to be used for general corporate purposes, the advancement of its clinical-stage vaccine candidates and its preclinical research programs, manufacturing and process development activities, capital expenditures and other strategic purposes.
The securities described above are being offered by Novavax pursuant to its registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC). This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The offering may be made only by means of the preliminary prospectus supplement and the prospectus relating to the proposed offering, copies of which may be obtained, when available, from Citigroup and JP Morgan, Attention: Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone: (866) 803-9204.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.
Forward-Looking Statements
Statements contained in this release, including those relating to the sale of common stock, and those statements using words such as "expects" and "intends" are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to successfully complete the offering on terms and conditions satisfactory to us; the possible adverse impact on the market price of our shares of common stock due to the dilutive effect of the securities to be sold in the offering; capital market risks; our ability to raise additional capital when needed; and other risk factors identified from time to time in the reports we file with Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which are available at www.sec.gov. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
CONTACT: Barclay Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
http://media.globenewswire.com/cache/14446/small/21693.jpg
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwODQ2MDgjMTQ0NDY=
Alibaba aims for good fortune with 8/8 IPO
http://blogs.marketwatch.com/thetell/2014/06/04/alibaba-aims-for-good-fortune-with-88-ipo/
Alibaba is reportedly targeting an August 8 trading debut in what’s expected to be the biggest initial public offering this year.
Alibaba co-founders Jack Ma and Joe Tsai are both keen on an Aug. 8, or 8-8, launch, as “eight” in Chinese denotes “fortune,” according to a Bloomberg report, citing unnamed sources.
Alibaba spokeswoman Ashley Zandy declined to comment.
It’s not the first time that the number 8 has figured prominently in events related to China. The 2008 Beijing Olympics kicked off on August 8.
Ben Lee, a co-founder of Glogou, a Silicon Valley online marketing company, which bills itself as the U.S. version of Alibaba, said that plan makes sense, noting that “Alibaba likes such fortune numbers.”
He added that Alibaba.com, a division of Alibaba Group, had used the ticker symbol 1688, for its IPO in Hong Kong a few years ago. The company was later taken private.
But Lee did point out a possible practical problem for an Aug. 8 Alibaba IPO: It’s a Friday.
“I’m not sure if Friday would be good for investors because there are not too many buyers on a Friday,” Lee told MarketWatch.
But there are some notable exceptions to this. Facebook went public on May 18, 2012, a Friday. Twitter, the last big tech IPO, went public on Nov. 7, a Thursday.
Still, setting a date for when it begins trading may not be that easy for Alibaba, which filed for an IPO in early May.
The Chinese Internet powerhouse is presumably now responding to questions from the Securities and Exchange Commission. That process has to be completed before Alibaba can begin its roadshow, where the company can pitch investors directly.
It’s difficult to determine how long this process will take. And the company must also consider uncertainty in the U.S. stock market.
– Benjamin Pimentel
$GLUU - Glu Mobile Closes $34.5 Million Public Offering of Common Stock
4:05 PM ET 6/4/14 | BusinessWire
Glu Mobile Inc. (NASDAQ:GLUU), a leading global developer and publisher of free-to-play games for smartphone and tablet devices, announced the closing of an underwritten public offering of 9,861,250 shares of its common stock at $3.50 per share for gross proceeds of approximately $34.5 million. The aggregate amount of common shares sold reflects the exercise in full by the underwriters of their option to purchase up to 1,286,250 additional shares of common stock to cover overallotments.
Glu received net proceeds of approximately $32.4 million from the sale of common stock, after deducting the underwriting discounts and estimated offering expenses. Glu intends to use the net proceeds from the offering for working capital and other general corporate purposes, including the acquisition of, or investment in, companies, technologies, products or assets that complement Glu's business.
Cowen and Company, LLC and Stifel acted as the joint book-running managers for the offering and Needham & Company and Northland Securities, Inc. acted as co-managers for the offering.
The offering was made pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). A final prospectus supplement and accompanying prospectus describing the terms of the offering were filed with the SEC. Before investing in Glu, you should read the prospectus supplement and the accompanying prospectus, and other documents that Glu has filed or will file with the SEC, for information about Glu Mobile and this offering.
Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806), or Stifel, Attention: Prospectus Dept., One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720. The final prospectus supplement and accompanying prospectus are also available on the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Forward-Looking Statements
This press release contains certain "forward-looking statements" related to the businesses of Glu Mobile Inc., which can be identified by the use of forward-looking terminology such as "believes," "expects," "plans" or similar expressions, including expectations regarding the planned use of the net proceeds from the offering. Such forward-looking statements involve known and unknown risks and uncertainties, including, but not limited to, the anticipated use of the proceeds of the offering, which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in the United States or internationally. Certain of these risks and uncertainties are or will be described in greater detail in our public filings with the SEC. Glu is not under obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140604006067r1&sid=cmtx6&distro=nx
SOURCE: Glu Mobile Inc.
Investor Relations Contact:
ICR, Inc.
Seth Potter, 646-277-1230
ir@glu.com
ONCS - Just had my StarBuck's Coffee today! I like this one. The company’s presentation by Robert Pierce, M.D., OncoSec Chief Medical Officer, is scheduled to begin at 1:00 p.m. PDT today.
$ONCS - OncoSec Medical Announces $16 Million Registered Direct Offering
9:04 AM ET 6/4/14 | BusinessWire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $16 million of securities in a registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 22,535,212 shares of its common stock at a price of $0.71 per share. Additionally, investors will receive warrants to purchase up to an aggregate of 7,887,325 shares of common stock at an exercise price of $0.90 per share for a term of five years.
The gross proceeds of the offering are approximately $16 million. Net proceeds, after deducting the placement agent's fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $14.9 million.
OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.
H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the transaction. Maxim Group LLC and Noble Financial Capital Markets acted as financial advisors to OncoSec in connection with the transaction.
The offering is expected to close on or about June 6, 2014, subject to customary closing conditions.
The securities described above are being offered by OncoSec pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission, or the SEC. A prospectus supplement related to the offering will be filed with the SEC. The securities may only be offered by means of a prospectus. Copies of the prospectus and prospectus supplement can be obtained directly from OncoSec and at the SEC's website at www.sec.gov or by request at H.C. Wainwright & Co., LLC by e-mailing placements@hcwco.com.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of OncoSec's common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140604005695r1&sid=cmtx6&distro=nx
SOURCE: OncoSec Medical Inc.
Investor Relations:
OncoSec Medical Inc.
Veronica Vallejo, CFO
855-662-6732
investors@oncosec.com
$GOOD - Gladstone Commercial Corporation Announces Pricing of Common Stock Offering
10:25 AM ET 6/3/14 | GlobeNewswire
Gladstone Commercial Corporation (Nasdaq:GOOD) (the "Company") today announced that it has priced its public offering of 1,400,000 shares of its common stock at a price to the public of $17.00 per share. The Company has also granted the underwriters a 30-day option to purchase up to 210,000 additional shares of common stock. Subject to customary closing conditions, the offering is expected to close on or about June 6, 2014. The net proceeds to the Company, after deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $22.5 million (exclusive of the underwriters' 30-day option to purchase additional shares of common stock).
Jefferies LLC and Janney Montgomery Scott LLC are serving as the joint book-running managers for the offering, Oppenheimer & Co. Inc., J.J.B. Hilliard, W.L. Lyons, LLC and Ladenburg Thalmann & Co. Inc. are serving as co-managers.
The Company intends to use the net proceeds from this offering to fund pending and future property acquisitions, repay existing indebtedness and for other general corporate purposes.
The offering is being conducted as a public offering under the Company's effective shelf registration statement filed with the Securities and Exchange Commission (File No. 333-190931). To obtain a copy of the final prospectus supplement and the accompanying prospectus for this offering, please contact: Jefferies LLC at 520 Madison Avenue, 2nd Floor, New York, NY, 10022, Attention: Equity Syndicate Prospectus Department, by calling (877) 547-6340 or by emailing Prospectus_Department@Jefferies.com.
This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Gladstone Commercial Corporation is a publicly-traded real estate investment trust that focuses on investing in and owning net leased industrial, commercial and retail real property and selectively making long-term industrial and commercial mortgage loans.
All statements contained in this press release, other than historical facts, may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements. Readers should not rely upon forward-looking statements because the matters they describe are subject to known and unknown risks and uncertainties that could cause the Company's business, financial condition, liquidity, results of operations, funds from operations or prospects to differ materially from those expressed in or implied by such statements. Such risks and uncertainties are disclosed under the caption "Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as filed with the Securities and Exchange Commission (the "SEC") on February 18, 2014, the final prospectus supplement for this offering and our other filings with the SEC. The Company cautions readers not to place undue reliance on any such forward-looking statements which speak only as of the date made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information contact Investor Relations at 703-287-5893.
http://media.globenewswire.com/cache/11441/small/26450.jpg
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwODQzMzgjMTE0NDE=
$API - Advanced Photonix, Inc. Announces Pricing Of Public Offering Of Common Stock
8:30 AM ET 5/30/14 | PR Newswire
Advanced Photonix, Inc.(R) (NYSE MKT: API) announced today that it priced an underwritten public offering of 5,391,304 shares of its Class A Common Stock at a public offering of $0.53 a share. Additionally, the Company has granted the underwriter an option exercisable for a 30-day period to the purchase up to an additional 808,696 shares of Class A Common Stock on the same terms and conditions. The Company plans to use the approximately $ 2.5 million in net proceeds to reduce its indebtedness and pay certain related fees.
http://photos.prnewswire.com/prnvar/20130304/LA69982LOGO
The shares of common stock are being sold pursuant to the Company's registration statement on Form S-3 (File No. 333-195689), which was declared effective by the Securities and Exchange Commission ("SEC") on May 12, 2014.
A prospectus supplement relating to the offering will be filed with the SEC. In connection with the offering, B. Riley & Co., LLC is acting as the sole underwriter. The offering of these shares will be made only by means of a prospectus and related prospectus supplement, copies of which can be obtained, when available, from B. Riley & Co., LLC, 11100 Santa Monica Blvd., Suite 800, Los Angeles, California 90025. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of the shares referred to in this press release in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.
About Advanced Photonix, Inc.Advanced Photonix, Inc.(R) (NYSE MKT: API) is a leading supplier of optoelectronic sensors, devices and instruments used by Test and Measurement, Process Control, Medical, Telecommunication and Homeland Security markets. The company has three product lines: Optosolutions focuses on enabling manufacturers to measure physical properties, including temperature, particular counting, color, and fluorescence for Medical, Homeland Security and Process Control applications. The Terahertz sensor product line is targeted to the Process Control, to enable quality control, and Security markets through nondestructive testing. The T-Gauge(R) sensor can measure subsurface physical properties, like multi-layers thicknesses, density, moisture content, anomaly detection and some chemical features, online and in real time. High-Speed Optical Receiver (HSOR) products are used by the telecommunication market in both telecommunication equipment and in test and measurement equipment utilized in the manufacturing of telecommunication equipment. For more information visit us on the web at www.advancedphotonix.com.
The information contained herein includes forward looking statements that are based on assumptions that management believes to be reasonable but are subject to inherent uncertainties and risks including, but not limited to, unforeseen technological obstacles which may prevent or slow the development and/or manufacture of new products; potential problems with the integration of the acquired company and its technology and possible inability to achieve expected synergies; obstacles to successfully combining product offerings and lack of customer acceptance of such offerings; limited (or slower than anticipated) customer acceptance of new products which have been and are being developed by the Company; and a decline in the general demand for optoelectronic products.
CONTACT: ir@advancedphotonix.com
Logo - http://photos.prnewswire.com/prnh/20130304/LA69982LOGO
SOURCE Advanced Photonix, Inc.
$GLUU - Glu Mobile Prices $30 Million Public Offering of Common Stock
9:01 AM ET 5/30/14 | BusinessWire
Glu Mobile Inc. (NASDAQ:GLUU), a leading global developer and publisher of free-to-play games for smartphone and tablet devices, priced an underwritten public offering of 8,575,000 shares of its common stock at $3.50 per share for gross proceeds of approximately $30.0 million. Glu has also granted the underwriters a 30-day option to purchase up to an additional 1,286,250 shares of common stock to cover overallotments, if any. The offering is expected to close on June 4, 2014, subject to satisfaction of customary closing conditions.
Glu expects to receive net proceeds of approximately $27.8 million from the sale of common stock, after deducting the underwriting discounts and estimated offering expenses. Glu intends to use the net proceeds from the offering for working capital and other general corporate purposes, including the acquisition of, or investment in, companies, technologies, products or assets that complement Glu's business.
Cowen and Company, LLC and Stifel are acting as the joint book-running managers for the offering and Needham & Company and Northland Securities, Inc. are acting as co-managers for the offering.
The offering is being made pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC. Before investing in Glu, you should read the prospectus supplement and the accompanying prospectus, and other documents that Glu has filed or will file with the SEC, for information about Glu and this offering.
When available, copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806), or Stifel, Attention: Prospectus Dept., One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720. The final prospectus supplement and accompanying prospectus also will be available on the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Forward-Looking Statements
This press release contains certain "forward-looking statements" related to the business of Glu Mobile Inc., which can be identified by the use of forward-looking terminology such as "believes," "expects," "plans" or similar expressions, including expectations regarding the completion of and anticipated proceeds from the proposed public offering, and the planned use of such proceeds. Such forward-looking statements involve known and unknown risks and uncertainties, including, but not limited to, whether or not Glu will consummate the offering, the anticipated use of the proceeds of the offering, which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in the United States or internationally. Certain of these risks and uncertainties are or will be described in greater detail in our public filings with the SEC. Glu is not under obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140530005359r1&sid=cmtx6&distro=nx
SOURCE: Glu Mobile Inc.
Investor Relations Contact:
ICR, Inc.
Seth Potter, 646-277-1230
ir@glu.com
oldie but goodie...
$DARA - DARA BioSciences, Inc. Announces Pricing of $12.5 Million Public Offering
8:47 AM ET 5/30/14 | Marketwire
DARA BioSciences, Inc. (NASDAQ: DARA) (the "Company"), an oncology supportive care specialty pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from cancer treatments, today announced the pricing of a public offering and the entry into definitive agreements with investors which included certain officers and directors of the Company for the sale of securities with gross proceeds to the Company of approximately $12.5 million.
The closing of the offering is expected to take place on or about June 4, 2014, subject to the satisfaction of customary closing conditions.
The Company estimates that the net proceeds from the offering will be approximately $11.3 million, after deducting placement agent fees and estimated offering expenses payable by the Company (and excluding potential proceeds from any exercise of the warrants). The Company currently intends to use the net proceeds of the offering (i) to fund commercial activities related to its product portfolio and the Mission Pharmacal products, including the Company's obligations in connection with its agreements with Mission and Alamo, (ii) to fund the acquisition of late stage/approved products to augment the Company's existing portfolio of supportive care products, (iii) to evaluate whether further internal development of KRN 5500 would be beneficial to the Company's partnering efforts and to undertake certain development activities as appropriate and (iv) for working capital and general corporate purposes.
Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT: LTS), acted as the lead placement agent in connection with the offering. H.C. Wainwright & Co., LLC served as co-placement agent in connection with the offering.
Under the terms of the agreements, the Company will issue registered shares of Series C-1 Convertible Preferred Stock ("Series C-1 Preferred Stock") with an aggregate stated value of approximately $12.5 million, which subject to certain ownership limitations is convertible at the option of the holders into a total of approximately 11.26 million shares of common stock of the Company at a conversion price of $1.11 per share. In the offering, the Company will also issue to the investors immediately-exercisable registered warrants to purchase up to an aggregate of approximately 11.26 million shares of common stock at an exercise price of $1.67 per share, with half of the warrants exercisable for a five-year term and half of the warrants exercisable for a thirteen-month term. The Series C-1 Preferred Stock and warrants described above (and the shares issuable from time to time upon conversion or exercise thereof) are being offered by the Company pursuant to the Company's Registration Statement on Form S-1 (File No. 333-193054) filed with the Securities and Exchange Commission ("SEC") which became effective on May 29, 2014. When filed with the SEC, electronic copies of the final prospectus for the offering can be obtained at the SEC's website at http://www.sec.gov, or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 570 Lexington Avenue, 11th Floor, New York, New York 10022, by calling (212) 409-2000 or by e-mailing prospectus@ladenburg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About DARA BioSciences, Inc.
DARA BioSciences Inc. of Raleigh, North Carolina, is an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments.
DARA holds exclusive U.S. marketing rights to both Soltamox® (tamoxifen citrate) oral solution and Gelclair®. DARA licensed the U.S. rights to Soltamox® from UK-based Rosemont Pharmaceuticals, Ltd., and Gelclair® from the Helsinn Group in Switzerland. Under an agreement with Innocutis, DARA also markets Bionect® (hyaluronic acid sodium salt, 0.2%).
Soltamox® (tamoxifen citrate) oral solution, the only liquid form of tamoxifen, is indicated for the treatment of metastatic breast cancer, the adjuvant treatment of node-positive breast cancer in postmenopausal women, the reduction in risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS), and for the reduction of the incidence of breast cancer in women at high risk for breast cancer. Currently, there are more than 1.8 million prescriptions of tamoxifen written on an annual basis in the United States. Between 30 and 70 percent of patients fail to complete their prescribed course of treatment, thereby diminishing its benefits in reducing the risk of breast cancer recurrence.
Tamoxifen Important Safety Information
Tamoxifen citrate is contraindicated in women who require concomitant coumadin-type anticoagulant therapy, in women with a history of deep vein thrombosis or pulmonary embolus, and in women with known hypersensitivity to the drug or any of its ingredients.
Serious and life-threatening events associated with tamoxifen in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism.
The most common adverse reactions to tamoxifen treatment are (incidence > 20%) hot flashes, fluid retention, vaginal discharge, vaginal bleeding, vasodilatation, nausea, irregular menses, weight loss, and musculoskeletal events.
Tamoxifen carries the following Boxed Warning:
WARNING -- For Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for Breast Cancer: Serious and life-threatening events associated with tamoxifen in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism. Incidence rates for these events were estimated from the NSABP P-1 trial (see CLINICAL PHARMACOLOGY, Clinical Studies, Reduction in Breast Cancer Incidence In High Risk Women). Uterine malignancies consist of both endometrial adenocarcinoma (incidence rate per 1,000 women-years of 2.20 for tamoxifen vs. 0.71 for placebo) and uterine sarcoma (incidence rate per 1,000 women-years of 0.17 for tamoxifen vs. 0.0 for placebo)*. For stroke, the incidence rate per 1,000 women-years was 1.43 for tamoxifen vs. 1.00 for placebo**. For pulmonary embolism, the incidence rate per 1,000 women-years was 0.75 for tamoxifen versus 0.25 for placebo**. Some of the strokes, pulmonary emboli, and uterine malignancies were fatal. Health care providers should discuss the potential benefits versus the potential risks of these serious events with women at high risk of breast cancer and women with DCIS considering tamoxifen to reduce their risk of developing breast cancer. The benefits of tamoxifen outweigh its risks in women already diagnosed with breast cancer.
*Updated long-term follow-up data (median length of follow-up is 6.9 years) from NSABP P-1 study. See WARNINGS, Effects on the Uterus-Endometrial Cancer and Uterine Sarcoma in Prescribing Information. **See Table 3 under CLINICAL PHARMACOLOGY, Clinical Studies in Prescribing Information.
The full Prescribing Information for Soltamox is available at www.soltamox.com/prescribing-information.
Gelclair® is an alcohol-free bioadherent oral rinse gel for rapid and effective relief of pain associated with oral mucositis caused by chemotherapy and radiation treatment. Gelclair should not be used by patients with a known or suspected hypersensitivity to the product or any of its ingredients. DARA licensed the U.S. rights to Soltamox from UK-based Rosemont Pharmaceuticals, Ltd., and Gelclair from the Helsinn Group in Switzerland. Under an agreement with Innocutis, DARA also markets Bionect® (hyaluronic acid sodium salt, 0.2%) a topical treatment for skin irritation and burns associated with radiation therapy, in U.S. oncology/radiology markets. Bionect should not be used by patients with known hypersensitivity to any of its ingredients. For further information on Gelclair and Bionect and the Full Prescribing Information please visit www.Gelclair.com and www.Bionect.com.
DARA is focused on expanding its portfolio of oncology supportive care products in the United States, via in-licensing and/or partnering of complementary late-stage and approved products. In addition, the company wishes to identify a strategic partner for the clinical development of KRN5500, currently in Phase 2 for the treatment of chronic, treatment refractory, chemotherapy-induced peripheral neuropathy (CCIPN). The FDA has designated KRN5500 as a Fast Track Drug, and has granted DARA Orphan Drug Designation for the treatment of painful, chronic chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics (CCIPN).
In early 2014, DARA kicked off its new partnership with Alamo Pharma Services, a subsidiary of Mission Pharmacal, in deploying a dedicated 20-person national sales team in the U.S. oncology market. In addition to promoting DARA's products Soltamox, Gelclair and Bionect, this specialized oncology supportive care sales team also provides clinicians with access to three Mission Pharmacal products: Ferralet® 90 (for anemia), BINOSTO® (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis), and Aquoral® (for chemotherapy/radiation therapy-induced dry mouth).
Important Safety Information and full Prescribing Information for Mission Pharmacal's products may be found at: www.Ferralet.com, www.Binosto.com, and www.Aquoral.com.
For more information please visit our web site at www.darabio.com.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks and uncertainties. Forward-looking statements are based on the current expectations, estimates, forecasts and projections regarding management's beliefs and assumptions. In some cases, you can identify forward looking statements by terminology such as "may," "will," "should," "hope," "expects," "intends," "plans," "anticipates," "contemplates," "believes," "estimates," "predicts," "projects," "potential," "continue," and other similar terminology or the negatives of those terms. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Important factors that could cause actual results to differ materially from the expectations described in these forward-looking statements are set forth under the caption "Risk Factors" in DARA's most recent Annual Report on Form 10-K, filed with the SEC on February 4, 2014, and DARA's other filings with the SEC from time to time. Those factors include risks and uncertainties relating to DARA's ability to timely commercialize and generate revenues or profits from Soltamox, Gelclair, Bionect or other products given that DARA only recently hired its initial sales force and DARA's lack of history as a revenue-generating company, DARA's ability to achieve the desired results from the agreements with Mission and Alamo, FDA and other regulatory risks relating to DARA's ability to market Soltamox, Gelclair, Bionect or other products in the United States or elsewhere, DARA's ability to in-license and/or partner products, DARA's current cash position and its need to raise additional capital in order to be able to continue to fund its operations, DARA's ability to raise sufficient capital and on favorable terms and the stockholder dilution that will result from the offering described in this press release and that may result from future financings, the current regulatory environment in which DARA sells its products, the market acceptance of those products, dependence on partners, successful performance under collaborative and other commercial agreements, competition, the strength of DARA's intellectual property and the intellectual property of others, the potential delisting of DARA's common stock from the NASDAQ Capital Market, and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission ("SEC"). Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
View data
Contact: Media David Connolly LaVoieHealthSciences 617-374-8800, Ext. 108 dconnolly@lavoiegroup.com Corporate Jim Polson FTI Consulting 312 553 6730 Jim.polson@fticonsulting.com
SOURCE: DARA BioSciences, Inc.
mailto:dconnolly@lavoiegroup.com
mailto:Jim.polson@fticonsulting.com
$GNSZ - GenSpera Announces $3.33 Million Registered Public Offering
8:53 AM ET 5/29/14 | BusinessWire
GenSpera, Inc. (OTCQB:GNSZ) announced that it has entered into definitive agreements with investors to purchase an aggregate of approximately $3.33 million units, in a registered public offering, at a price per unit of $0.80. Each unit consists of one share of common stock, one-half of a Series A warrant, one Series B warrant and one Series C warrant. The Series A warrants will be exercisable into approximately 2.1 million shares of the company's common stock at an exercise price of $1.15 per share, are exercisable immediately and have a term of exercise equal to five years. The Series B warrants will be exercisable into approximately 4.2 million shares of the company's common stock at an exercise price of $0.85, are exercisable immediately and have a term of exercise of 9 months. The Series C warrants will be exercisable into approximately 4.2 million shares of the company's common stock at an exercise price of $0.85, are immediately exercisable and have a term of exercise of one year. The anticipated closing of the offering is expected on or about June 3, 2014, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co., LLC, acted as the exclusive placement agent in connection with the offering.
The securities described above are being offered by GenSpera, Inc. pursuant to the registration statement (File No. 333-194678), which was declared effective by the United States Securities and Exchange Commission, or the SEC, on May 23, 2014. A prospectus supplement related to the offering will be filed with the SEC. The securities may only be offered by means of a prospectus. Copies of the prospectus and prospectus supplement can be obtained directly from GenSpera, Inc. and at the SEC's website at www.sec.gov or by request at H.C. Wainwright & Co., LLC by e-mailing placements@hcwco.com.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of GenSpera Inc.'s common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov.
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma.
For more information, please visit the Company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140529005680r1&sid=cmtx6&distro=nx
SOURCE: GenSpera, Inc.
Company:
GenSpera, Inc.
Craig Dionne, PhD, 210-479-8112
CEO
or
Media:
Planet Communications
Deanne Eagle, 917-837-5866
or
Investors:
BPC Financial Marketing
John Baldissera, 800-368-1217
Followers
|
39
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2200
|
Created
|
03/07/13
|
Type
|
Free
|
Moderator starbuxsux | |||
Assistants |
Company Name | Symbol | Market | Price | Shares | Offer Amount | Date Priced |
---|---|---|---|---|---|---|
LEHIGH GAS PARTNERS LP | LGP | New York Stock Exchange | $28.10 | 3,100,000 | $87,110,000 | 12/4/2013 |
See Also:Recently Priced Initial Public Offerings (IPOs)
$ECTE - ECHO THERAPEUTICS Echo Therapeutics Announces Pricing of Common Stock @ $9.50 per share [YOU SEE WHAT HAPPENED...NO NEED TO EXPLAIN LOL] PHILADELPHIA, Dec. 20, 2012 /PRNewswire/ 7:22pm Echo Therapeutics Announces Closing of Public Offering of Common Stock [Not long after.....KABOOOOOOOM!!!!!!!!] PHILADELPHIA, Dec. 27, 2012 /PRNewswire/ 3:15pm |
---|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |